Download PDF
CC BY-NC-ND 4.0 · Journal of Gastrointestinal and Abdominal Radiology 2020; 3(01): 040-052
DOI: 10.1055/s-0039-3401645
Review Article

Pancreatic Cancer Imaging: What the Surgeon Wants to Know?

Ajaykumar C. Morani
1   Department of Radiology, University of Texas MD Anderson Cancer Center, Houston, Texas, United States
,
Ahmed Taher
2   Department of Diagnostic Radiology, University of Texas MD Anderson Cancer Center, Houston, Texas, United States
,
Nisha S. Ramani
3   Department of Anatomic Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, United States
,
Corey T. Jensen
1   Department of Radiology, University of Texas MD Anderson Cancer Center, Houston, Texas, United States
,
Asif Patel
4   Department of MBA, IGlobal University, Vienna, Virginia, United States
,
Bilal Mujtaba
1   Department of Radiology, University of Texas MD Anderson Cancer Center, Houston, Texas, United States
› Author Affiliations Funding None.
› Further Information
   Permissions and Reprints

Abstract

Pancreatic cancer is rare but is one of the deadliest cancers. Complete surgical removal of the cancer with negative margins is the only potentially curative treatment. However, majority of the cases present with distant metastases and/or locally advanced disease, and only a limited subset (up to 20%) of patients are surgical candidates. Therefore, accurate staging of pancreatic cancer is very important for treatment planning. It is very important to distinguish between patients who are surgical candidates and those who would need palliative treatment. Imaging plays a crucial role in the detection of the primary tumor, vascular involvement and variants, metastasis, prediction of resectability, and monitoring treatment response. High-resolution multidetector computed tomography (CT) is the primary imaging modality of choice for diagnosing and staging pancreatic cancers. Nevertheless, integration of ultrasound, CT, and magnetic resonance imaging (MRI) may be needed for accurate determination of the tumor extent and optimal management. Herein, we aim to provide a radiological review for “what the surgeon wants to know about pancreatic cancer?” In this review, we highlight the main types of invasive pancreatic cancers and discuss the role of imaging in determining the resectability of pancreatic tumors and the role of neoadjuvant treatment in downstaging borderline or unresectable cases in addition to featuring significant postsurgical complications.

Keywords

pancreatic cancer - surgeons - borderline resectable - malignant IPMN - malignant pancreatic neuroendocrine tumor


Publication History

Article published online:
29 April 2020

© .

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69 (01) 7-34
    CrossrefPubMedGoogle Scholar
  • 2 Malvezzi M, Carioli G, Bertuccio P. et al. European cancer mortality predictions for the year 2017, with focus on lung cancer. Ann Oncol 2017; 28 (05) 1117-1123
    CrossrefPubMedGoogle Scholar
  • 3 Clancy TE. Surgery for pancreatic cancer. Hematol Oncol Clin North Am 2015; 29 (04) 701-716
    CrossrefPubMedGoogle Scholar
  • 4 De La Cruz MS, Young AP, Ruffin MT. Diagnosis and management of pancreatic cancer. Am Fam Physician 2014; 89 (08) 626-632
    PubMedGoogle Scholar
  • 5 Jeune F, Coriat R, Prat F, Dousset B, Vaillant JC, Gaujoux S. Pancreatic cancer surgical management. Presse Med 2019; 48 (3 Pt 2) e147-e158
    CrossrefPubMedGoogle Scholar
  • 6 Hartwig W, Werner J, Jäger D, Debus J, Büchler MW. Improvement of surgical results for pancreatic cancer. Lancet Oncol 2013; 14 (11) e476-e485
    CrossrefPubMedGoogle Scholar
  • 7 Tempero MA, Malafa MP, Al-Hawary M. et al. Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2017; 15 (08) 1028-1061
    CrossrefPubMedGoogle Scholar
  • 8 Varadhachary GR, Tamm EP, Abbruzzese JL. et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 2006; 13 (08) 1035-1046
    CrossrefPubMedGoogle Scholar
  • 9 Reynolds RB, Folloder J. Clinical management of pancreatic cancer. J Adv Pract Oncol 2014; 5 (05) 356-364
    PubMedGoogle Scholar
  • 10 Lopez NE, Prendergast C, Lowy AM. Borderline resectable pancreatic cancer: definitions and management. World J Gastroenterol 2014; 20 (31) 10740-10751
    CrossrefPubMedGoogle Scholar
  • 11 Zaky AM, Wolfgang CL, Weiss MJ, Javed AA, Fishman EK, Zaheer A. Tumor-vessel relationships in pancreatic ductal adenocarcinoma at multidetector CT: different classification systems and their influence on treatment planning. Radiographics 2017; 37 (01) 93-112
    CrossrefPubMedGoogle Scholar
  • 12 Bockhorn M, Uzunoglu FG, Adham M. et al; International Study Group of Pancreatic Surgery. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 2014; 155 (06) 977-988
    CrossrefPubMedGoogle Scholar
  • 13 Scialpi M, Reginelli A, D’Andrea A. et al. Pancreatic tumors imaging: an update. Int J Surg 2016; 28 (01) (Suppl. 01) S142-S155
    CrossrefPubMedGoogle Scholar
  • 14 Fenchel S, Boll DT, Fleiter TR, Brambs HJ, Merkle EM. Multislice helical CT of the pancreas and spleen. Eur J Radiol 2003; 45 (Suppl. 01) S59-S72
    CrossrefPubMedGoogle Scholar
  • 15 Seo JW, Hwang HK, Lee M. et al. Normal postoperative computed tomography findings after a variety of pancreatic surgeries. Korean J Radiol 2017; 18 (02) 299-308
    CrossrefPubMedGoogle Scholar
  • 16 Li JH, He R, Li YM, Cao G, Ma QY, Yang WB. Endoscopic ultrasonography for tumor node staging and vascular invasion in pancreatic cancer: a meta-analysis. Dig Surg 2014; 31 (4-5) 297-305
    CrossrefPubMedGoogle Scholar
  • 17 Low G, Panu A, Millo N, Leen E. Multimodality imaging of neoplastic and nonneoplastic solid lesions of the pancreas. Radiographics 2011; 31 (04) 993-1015
    CrossrefPubMedGoogle Scholar
  • 18 Rishi A, Goggins M, Wood LD, Hruban RH. Pathological and molecular evaluation of pancreatic neoplasms. Semin Oncol 2015; 42 (01) 28-39
    CrossrefPubMedGoogle Scholar
  • 19 Dudeja V, Allen PJ. Premalignant cystic neoplasms of the pancreas. Semin Oncol 2015; 42 (01) 70-85
    CrossrefPubMedGoogle Scholar
  • 20 Feig BW, Ching CD. The MD Anderson Surgical Oncology Handbook. 6th ed. Philadelphia, PA: Wolters Kluwer Health Adis (ESP). 2018
    Google Scholar
  • 21 Krech RL, Walsh D. Symptoms of pancreatic cancer. J Pain Symptom Manage 1991; 6 (06) 360-367
    CrossrefPubMedGoogle Scholar
  • 22 American gastroenterological association medical position statement: epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology 1999; 117 (06) 1463-1484
    CrossrefPubMedGoogle Scholar
  • 23 Sah RP, Nagpal SJ, Mukhopadhyay D, Chari ST. New insights into pancreatic cancer-induced paraneoplastic diabetes. Nat Rev Gastroenterol Hepatol 2013; 10 (07) 423-433
    CrossrefPubMedGoogle Scholar
  • 24 Loosen SH, Neumann UP, Trautwein C, Roderburg C, Luedde T. Current and future biomarkers for pancreatic adenocarcinoma. Tumour Biol 2017; 39 (06) 1010428317692231
    Google Scholar
  • 25 Pappas SG, Christians KK, Tolat PP. et al. Staging chest computed tomography and positron emission tomography in patients with pancreatic adenocarcinoma: utility or futility?. HPB (Oxford) 2014; 16 (01) 70-74
    CrossrefPubMedGoogle Scholar
  • 26 Wong JC, Lu DS. Staging of pancreatic adenocarcinoma by imaging studies. Clin Gastroenterol Hepatol 2008; 6 (12) 1301-1308
    CrossrefPubMedGoogle Scholar
  • 27 Callery MP, Chang KJ, Fishman EK. Talamonti MS, William Traverso L, Linehan DC. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 2009; 16 (07) 1727-1733
    CrossrefPubMedGoogle Scholar
  • 28 Tamm EP, Balachandran A, Bhosale PR. et al. Imaging of pancreatic adenocarcinoma: update on staging/resectability. Radiol Clin North Am 2012; 50 (03) 407-428
    CrossrefPubMedGoogle Scholar
  • 29 Brennan DD, Zamboni GA, Raptopoulos VD, Kruskal JB. Comprehensive preoperative assessment of pancreatic adenocarcinoma with 64-section volumetric CT. Radiographics 2007; 27 (06) 1653-1666
    CrossrefPubMedGoogle Scholar
  • 30 Granata V, Fusco R, Catalano O. et al. Multidetector computer tomography in the pancreatic adenocarcinoma assessment: an update. Infect Agent Cancer 2016; 11: 57
    CrossrefPubMedGoogle Scholar
  • 31 Ichikawa T, Erturk SM, Sou H. et al. MDCT of pancreatic adenocarcinoma: optimal imaging phases and multiplanar reformatted imaging. AJR Am J Roentgenol 2006; 187 (06) 1513-1520
    CrossrefPubMedGoogle Scholar
  • 32 Ichikawa T, Haradome H, Hachiya J. et al. Pancreatic ductal adenocarcinoma: preoperative assessment with helical CT versus dynamic MR imaging. Radiology 1997; 202 (03) 655-662
    CrossrefPubMedGoogle Scholar
  • 33 Prokesch RW, Chow LC, Beaulieu CF. Bammer R, Jeffrey RB Jr. Isoattenuating pancreatic adenocarcinoma at multi-detector row CT: secondary signs. Radiology 2002; 224 (03) 764-768
    CrossrefPubMedGoogle Scholar
  • 34 Tummala P, Junaidi O, Agarwal B. Imaging of pancreatic cancer: an overview. J Gastrointest Oncol 2011; 2 (03) 168-174
    PubMedGoogle Scholar
  • 35 Andersson R, Vagianos CE, Williamson RC. Preoperative staging and evaluation of resectability in pancreatic ductal adenocarcinoma. HPB (Oxford) 2004; 6 (01) 5-12
    CrossrefPubMedGoogle Scholar
  • 36 Takakura K, Sumiyama K, Munakata K. et al. Clinical usefulness of diffusion-weighted MR imaging for detection of pancreatic cancer: comparison with enhanced multidetector-row CT. Abdom Imaging 2011; 36 (04) 457-462
    CrossrefPubMedGoogle Scholar
  • 37 Peddu P, Quaglia A, Kane PA, Karani JB. Role of imaging in the management of pancreatic mass. Crit Rev Oncol Hematol 2009; 70 (01) 12-23
    CrossrefPubMedGoogle Scholar
  • 38 Lee JK, Kim AY, Kim PN, Lee MG, Ha HK. Prediction of vascular involvement and resectability by multidetector-row CT versus MR imaging with MR angiography in patients who underwent surgery for resection of pancreatic ductal adenocarcinoma. Eur J Radiol 2010; 73 (02) 310-316
    CrossrefPubMedGoogle Scholar
  • 39 Miller FH, Rini NJ, Keppke AL. MRI of adenocarcinoma of the pancreas. AJR Am J Roentgenol 2006; 187 (04) W365-W374
    CrossrefPubMedGoogle Scholar
  • 40 Cuneo KC, Chenevert TL, Ben-Josef E. et al. A pilot study of diffusion-weighted MRI in patients undergoing neoadjuvant chemoradiation for pancreatic cancer. Transl Oncol 2014; 7 (05) 644-649
    CrossrefPubMedGoogle Scholar
  • 41 Lin F, Staerkel G. Cytologic criteria for well differentiated adenocarcinoma of the pancreas in fine-needle aspiration biopsy specimens. Cancer 2003; 99 (01) 44-50
    PubMedGoogle Scholar
  • 42 Siddiqui AA, Brown LJ, Hong SK. et al. Relationship of pancreatic mass size and diagnostic yield of endoscopic ultrasound-guided fine needle aspiration. Dig Dis Sci 2011; 56 (11) 3370-3375
    CrossrefPubMedGoogle Scholar
  • 43 Gonçalves B, Soares JB, Bastos P. Endoscopic ultrasound in the diagnosis and staging of pancreatic cancer. GE Port J Gastroenterol 2015; 22 (04) 161-171
    CrossrefPubMedGoogle Scholar
  • 44 Gress FG, Hawes RH, Savides TJ. et al. Role of EUS in the preoperative staging of pancreatic cancer: a large single-center experience. Gastrointest Endosc 1999; 50 (06) 786-791
    CrossrefPubMedGoogle Scholar
  • 45 Krishna NB, Mehra M, Reddy AV, Agarwal B. EUS/EUS-FNA for suspected pancreatic cancer: influence of chronic pancreatitis and clinical presentation with or without obstructive jaundice on performance characteristics. Gastrointest Endosc 2009; 70 (01) 70-79
    CrossrefPubMedGoogle Scholar
  • 46 Bhutani MS, Gress FG, Giovannini M. et al; No Endosonographic Detection of Tumor (NEST) Study. The No Endosonographic Detection of Tumor (NEST) Study: a case series of pancreatic cancers missed on endoscopic ultrasonography. Endoscopy 2004; 36 (05) 385-389
    Article in Thieme ConnectPubMedGoogle Scholar
  • 47 Tio TL, Tytgat GN, Cikot RJ, Houthoff HJ, Sars PR. Ampullopancreatic carcinoma: preoperative TNM classification with endosonography. Radiology 1990; 175 (02) 455-461
    CrossrefPubMedGoogle Scholar
  • 48 Grimm H, Maydeo A, Soehendra N. Endoluminal ultrasound for the diagnosis and staging of pancreatic cancer. Baillieres Clin Gastroenterol 1990; 4 (04) 869-888
    CrossrefPubMedGoogle Scholar
  • 49 Wakabayashi H, Nishiyama Y, Otani T. et al. Role of 18F-fluorodeoxyglucose positron emission tomography imaging in surgery for pancreatic cancer. World J Gastroenterol 2008; 14 (01) 64-69
    CrossrefPubMedGoogle Scholar
  • 50 Pery C, Meurette G, Ansquer C, Frampas E, Regenet N. Role and limitations of 18F-FDG positron emission tomography (PET) in the management of patients with pancreatic lesions. Gastroenterol Clin Biol 2010; 34 (8-9) 465-474
    CrossrefPubMedGoogle Scholar
  • 51 Heinrich S, Goerres GW, Schäfer M. et al. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg 2005; 242 (02) 235-243
    CrossrefPubMedGoogle Scholar
  • 52 Kauhanen SP, Komar G, Seppänen MP. et al. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann Surg 2009; 250 (06) 957-963
    CrossrefPubMedGoogle Scholar
  • 53 Kunstman JW, Fonseca AL, Ciarleglio MM, Cong X, Hochberg A, Salem RR. Comprehensive analysis of variables affecting delayed gastric emptying following pancreaticoduodenectomy. J Gastrointest Surg 2012; 16 (07) 1354-1361
    CrossrefPubMedGoogle Scholar
  • 54 McIntyre CA, Winter JM. Diagnostic evaluation and staging of pancreatic ductal adenocarcinoma. Semin Oncol 2015; 42 (01) 19-27
    CrossrefPubMedGoogle Scholar
  • 55 Katz MH, Fleming JB, Bhosale P. et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer 2012; 118 (23) 5749-5756
    CrossrefPubMedGoogle Scholar
  • 56 Katz MH, Pisters PW, Evans DB. et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 2008; 206 (05) 833-846
    CrossrefPubMedGoogle Scholar
  • 57 Kim CB, Ahmed S, Hsueh EC. Current surgical management of pancreatic cancer. J Gastrointest Oncol 2011; 2 (03) 126-135
    PubMedGoogle Scholar
  • 58 Tran KT, Smeenk HG, van Eijck CH. et al. Pylorus preserving pancreaticoduodenectomy versus standard Whipple procedure: a prospective, randomized, multicenter analysis of 170 patients with pancreatic and periampullary tumors. Ann Surg 2004; 240 (05) 738-745
    CrossrefPubMedGoogle Scholar
  • 59 Whipple AO, Parsons WB, Mullins CR. Treatment of carcinoma of the ampulla of Vater. Ann Surg 1935; 102 (04) 763-779
    CrossrefPubMedGoogle Scholar
  • 60 Goh BK, Tan YM, Chung YF. et al. Critical appraisal of 232 consecutive distal pancreatectomies with emphasis on risk factors, outcome, and management of the postoperative pancreatic fistula: a 21-year experience at a single institution. Arch Surg 2008; 143 (10) 956-965
    CrossrefPubMedGoogle Scholar
  • 61 Wolfgang CL, Corl F, Johnson PT. et al. Pancreatic surgery for the radiologist, 2011: an illustrated review of classic and newer surgical techniques for pancreatic tumor resection. AJR Am J Roentgenol 2011; 197 (06) 1343-1350
    CrossrefPubMedGoogle Scholar
  • 62 Abrams RA, Lowy AM, O’Reilly EM, Wolff RA, Picozzi VJ, Pisters PW. Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol 2009; 16 (07) 1751-1756
    CrossrefPubMedGoogle Scholar
  • 63 Suker M, Beumer BR, Sadot E. et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol 2016; 17 (06) 801-810
    CrossrefPubMedGoogle Scholar
  • 64 Roeder F. Neoadjuvant radiotherapeutic strategies in pancreatic cancer. World J Gastrointest Oncol 2016; 8 (02) 186-197
    CrossrefPubMedGoogle Scholar
  • 65 Dalah E, Tai A, Oshima K, Hall WA, Erickson B, Li XA. PET-based treatment response assessment for neoadjuvant chemoradiation in pancreatic adenocarcinoma: an exploratory study. Transl Oncol 2018; 11 (05) 1104-1109
    CrossrefPubMedGoogle Scholar
  • 66 Adsay NV. Cystic neoplasia of the pancreas: pathology and biology. J Gastrointest Surg 2008; 12 (03) 401-404
    CrossrefPubMedGoogle Scholar
  • 67 Tanaka M, Chari S, Adsay V. et al; International Association of Pancreatology. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006; 6 (1-2) 17-32
    CrossrefPubMedGoogle Scholar
  • 68 Pelaez-Luna M, Chari ST, Smyrk TC. et al. Do consensus indications for resection in branch duct intraductal papillary mucinous neoplasm predict malignancy? A study of 147 patients. Am J Gastroenterol 2007; 102 (08) 1759-1764
    CrossrefPubMedGoogle Scholar
  • 69 Takasu N, Kimura W, Moriya T. et al. Intraductal papillary-mucinous neoplasms of the gastric and intestinal types may have less malignant potential than the pancreatobiliary type. Pancreas 2010; 39 (05) 604-610
    CrossrefPubMedGoogle Scholar
  • 70 Kallen ME, Naini BV. Intraductal oncocytic papillary neoplasms of the pancreas. Arch Pathol Lab Med 2016; 140 (09) 992-996
    CrossrefPubMedGoogle Scholar
  • 71 Salvia R, Fernández-del Castillo C, Bassi C. et al. Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg 2004; 239 (05) 678-685, discussion 685–687
    CrossrefPubMedGoogle Scholar
  • 72 Rodriguez JR, Salvia R, Crippa S. et al. Branch-duct intraductal papillary mucinous neoplasms: observations in 145 patients who underwent resection. Gastroenterology 2007; 133 (01) 72-79
    CrossrefPubMedGoogle Scholar
  • 73 Machado NO, Al Qadhi H, Al Wahibi K. Intraductal papillary mucinous neoplasm of pancreas. N Am J Med Sci 2015; 7 (05) 160-175
    CrossrefPubMedGoogle Scholar
  • 74 Song SJ, Lee JM, Kim YJ. et al. Differentiation of intraductal papillary mucinous neoplasms from other pancreatic cystic masses: comparison of multirow-detector CT and MR imaging using ROC analysis. J Magn Reson Imaging 2007; 26 (01) 86-93
    CrossrefPubMedGoogle Scholar
  • 75 Manfredi R, Graziani R, Motton M. et al. Main pancreatic duct intraductal papillary mucinous neoplasms: accuracy of MR imaging in differentiation between benign and malignant tumors compared with histopathologic analysis. Radiology 2009; 253 (01) 106-115
    CrossrefPubMedGoogle Scholar
  • 76 Procacci C, Megibow AJ, Carbognin G. et al. Intraductal papillary mucinous tumor of the pancreas: a pictorial essay. Radiographics 1999; 19 (06) 1447-1463
    CrossrefPubMedGoogle Scholar
  • 77 Salvia R, Crippa S, Falconi M. et al. Branch-duct intraductal papillary mucinous neoplasms of the pancreas: to operate or not to operate?. Gut 2007; 56 (08) 1086-1090
    CrossrefPubMedGoogle Scholar
  • 78 Chandwani R, Allen PJ. Cystic neoplasms of the pancreas. Annu Rev Med 2016; 67 (01) 45-57
    CrossrefPubMedGoogle Scholar
  • 79 Crippa S, Salvia R, Warshaw AL. et al. Mucinous cystic neoplasm of the pancreas is not an aggressive entity: lessons from 163 resected patients. Ann Surg 2008; 247 (04) 571-579
    CrossrefPubMedGoogle Scholar
  • 80 Falconi M, Bartsch DK, Eriksson B. et al; Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology 2012; 95 (02) 120-134
    CrossrefPubMedGoogle Scholar
  • 81 Yao JC, Hassan M, Phan A. et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26 (18) 3063-3072
    CrossrefPubMedGoogle Scholar
  • 82 Bosman FT, Carneiro F, Hruban R H, Theise N. WHO Classification of Tumours of the Digestive System. 4th ed. France: IARC 2010
  • 83 Rodallec M, Vilgrain V, Couvelard A. et al. Endocrine pancreatic tumours and helical CT: contrast enhancement is correlated with microvascular density, histoprognostic factors and survival. Pancreatology 2006; 6 (01/02) 77-85
    CrossrefPubMedGoogle Scholar
  • 84 Horton KM, Hruban RH, Yeo C, Fishman EK. Multi-detector row CT of pancreatic islet cell tumors. Radiographics 2006; 26 (02) 453-464
    CrossrefPubMedGoogle Scholar
  • 85 Katsuta E, Kudo A, Akashi T. et al. Macroscopic morphology for estimation of malignant potential in pancreatic neuroendocrine neoplasm. J Cancer Res Clin Oncol 2016; 142 (06) 1299-1306
    CrossrefPubMedGoogle Scholar
  • 86 Ichikawa T, Peterson MS, Federle MP. et al. Islet cell tumor of the pancreas: biphasic CT versus MR imaging in tumor detection. Radiology 2000; 216 (01) 163-171
    CrossrefPubMedGoogle Scholar
  • 87 Sundin A, Vullierme MP, Kaltsas G, Plöckinger U. Mallorca Consensus Conference participants. European Neuroendocrine Tumor Society. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology 2009; 90 (02) 167-183
    CrossrefPubMedGoogle Scholar
  • 88 Thoeni RF, Mueller-Lisse UG, Chan R. Do NK, Shyn PB. Detection of small, functional islet cell tumors in the pancreas: selection of MR imaging sequences for optimal sensitivity. Radiology 2000; 214 (02) 483-490
    CrossrefPubMedGoogle Scholar
  • 89 James PD, Tsolakis AV, Zhang M. et al. Incremental benefit of preoperative EUS for the detection of pancreatic neuroendocrine tumors: a meta-analysis. Gastrointest Endosc 2015; 81 (04) 848-856
    CrossrefPubMedGoogle Scholar
  • 90 Hofman MS, Kong G, Neels OC, Eu P, Hong E, Hicks RJ. High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. J Med Imaging Radiat Oncol 2012; 56 (01) 40-47
    CrossrefPubMedGoogle Scholar
  • 91 Busquets J, Ramírez-Maldonado E, Serrano T. et al. Surgical treatment of non-functioning pancreatic neuroendocrine tumours based on three clinical scenarios. Cir Esp 2016; 94 (10) 578-587
    CrossrefPubMedGoogle Scholar
  • 92 Perry RR, Vinik AI. Clinical review 72: diagnosis and management of functioning islet cell tumors. J Clin Endocrinol Metab 1995; 80 (08) 2273-2278
    PubMedGoogle Scholar